Free Trial
LON:FARN

Faron Pharmaceuticals Oy (FARN) Share Price, News & Analysis

Faron Pharmaceuticals Oy logo
GBX 165
0.00 (0.00%)
(As of 11/1/2024 ET)

About Faron Pharmaceuticals Oy Stock (LON:FARN)

Key Stats

Today's Range
165
165
50-Day Range
167
229.90
52-Week Range
85
370
Volume
17,480 shs
Average Volume
48,782 shs
Market Capitalization
£172.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is also developing bexmarilimab, which is in phase 2 clinical trial for indications of solid tumors; and in phase 1 clinical trial for indications of acute myeloid leukemia and myelodysplastic syndromes. In addition, it develops interferon beta-1a to prevent toxicities from CAR-T therapy in phase 2 clinical trial; and AOC3 inhibitor, which is in preclinical studies for indications of chemotherapy-induced neutropenia. Further, it develops Haematokine, an investigational AOC3 protein inhibitor that is used for regenerative medicines in hematological malignancies, as well as chemotherapy induced suppression of the bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Receive FARN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Faron Pharmaceuticals Oy and its competitors with MarketBeat's FREE daily newsletter.

FARN Stock News Headlines

Faron Pharmaceuticals Share Chat
Sell NVDA Now?
Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.
See More Headlines

FARN Stock Analysis - Frequently Asked Questions

Faron Pharmaceuticals Oy's stock was trading at GBX 305 on January 1st, 2024. Since then, FARN stock has decreased by 45.9% and is now trading at GBX 165.
View the best growth stocks for 2024 here
.

Shares of FARN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Faron Pharmaceuticals Oy investors own include Horizon Discovery Group plc (HZD.L) (HZD), Greencore Group (GNC), Premier African Minerals (PREM), Babcock International Group (BAB), Barclays (BARC), B&M European Value Retail (BME) and Coats Group (COA).

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
34
Year Founded
N/A

Profitability

Net Income
£-31,610,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£-725,000.00
Cash Flow
GBX 8.25 per share
Book Value
GBX 1 per share

Miscellaneous

Free Float
N/A
Market Cap
£172.62 million
Optionable
Not Optionable
Beta
0.36
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (LON:FARN) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners